John Pappajohn Acquires 100,000 Shares of Cancer Genetics Inc. (CGIX) Stock
Cancer Genetics Inc. (NASDAQ:CGIX) Director John Pappajohn bought 100,000 shares of the firm’s stock in a transaction that occurred on Monday, November 28th. The stock was purchased at an average cost of $1.45 per share, with a total value of $145,000.00. Following the completion of the transaction, the director now directly owns 2,420,709 shares in the company, valued at $3,510,028.05. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.
John Pappajohn also recently made the following trade(s):
- On Monday, November 14th, John Pappajohn bought 31,100 shares of Cancer Genetics stock. The stock was purchased at an average cost of $1.48 per share, with a total value of $46,028.00.
Shares of Cancer Genetics Inc. (NASDAQ:CGIX) opened at 1.50 on Thursday. The company’s market capitalization is $28.33 million. Cancer Genetics Inc. has a one year low of $1.10 and a one year high of $3.80. The firm’s 50-day moving average price is $1.52 and its 200-day moving average price is $1.91.
Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.05. Cancer Genetics had a negative net margin of 74.07% and a negative return on equity of 63.26%. The business earned $6.80 million during the quarter, compared to analyst estimates of $6.93 million. During the same period in the prior year, the business posted ($0.56) earnings per share. The company’s revenue was up 70.0% on a year-over-year basis. Analysts anticipate that Cancer Genetics Inc. will post ($1.17) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This report was originally published by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this report can be accessed at http://www.dailypolitical.com/2016/12/01/john-pappajohn-acquires-100000-shares-of-cancer-genetics-inc-cgix-stock.html.
A number of analysts recently commented on the company. Rodman & Renshaw assumed coverage on Cancer Genetics in a research report on Monday, September 26th. They issued a “buy” rating and a $6.00 target price for the company. Zacks Investment Research raised Cancer Genetics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Monday, November 7th. Finally, HC Wainwright initiated coverage on Cancer Genetics in a research report on Tuesday, September 27th. They issued a “buy” rating and a $6.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $7.19.
Hedge funds have recently bought and sold shares of the stock. Sabby Management LLC raised its stake in Cancer Genetics by 145.5% in the second quarter. Sabby Management LLC now owns 199,580 shares of the company’s stock worth $397,000 after buying an additional 118,280 shares in the last quarter. Perkins Capital Management Inc. boosted its stake in Cancer Genetics by 48.8% in the third quarter. Perkins Capital Management Inc. now owns 864,600 shares of the company’s stock valued at $1,513,000 after buying an additional 283,400 shares during the last quarter. Anson Funds Management LP acquired a new stake in Cancer Genetics during the third quarter valued at about $476,000. Fairbanks Capital Management Inc. boosted its stake in Cancer Genetics by 0.9% in the third quarter. Fairbanks Capital Management Inc. now owns 235,170 shares of the company’s stock valued at $411,000 after buying an additional 2,000 shares during the last quarter. Finally, Eagle Global Advisors LLC boosted its stake in Cancer Genetics by 69.3% in the second quarter. Eagle Global Advisors LLC now owns 84,320 shares of the company’s stock valued at $168,000 after buying an additional 34,510 shares during the last quarter. Institutional investors and hedge funds own 12.19% of the company’s stock.
Cancer Genetics Company Profile
Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Receive News & Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.